Ergoteles’s BioNTech BNTX Stock Holding History

Ergoteles’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3,179	Closed	-$478K	–	1285
2022 Q4	$478K	Buy	+3,179	New	+$489K	0.02%	719
2021 Q4	–	Sell	-33,276	Closed	-$9.08M	–	1255
2021 Q3	$9.08M	Sell	33,276 -20,991	-39%	-$6.67M	0.33%	77
2021 Q2	$12.1M	Buy	54,267 +31,478	+138%	+$5.94M	0.28%	106
2021 Q1	$2.49M	Buy	+22,789	New	+$2.42M	0.08%	250

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

AGA

Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return

Ergoteles's BNTX Position: Q1 2023 in Review

Ergoteles sold out of BioNTech (BNTX) in Q1 2023, closing a stake of 3,179 shares — an estimated $478K sold.

Ergoteles first reported a position in BNTX in Q1 2021 and held it in 4 quarters. The position peaked at $12.1M in Q2 2021. 282 funds tracked by Wall St. Rank hold BNTX as of Q1 2023.

Ergoteles reported no remaining BioNTech position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 3,179 BioNTech shares in Q1 2023, an estimated $478K.
Ergoteles first reported a position in BioNTech in Q1 2021 and held it in 4 quarters.
Ergoteles's BioNTech position peaked at $12.1M in Q2 2021.
282 funds tracked by Wall St. Rank held BioNTech as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.